By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Similar Posts
Alembic Pharmaceuticals Limited Units I & II – 05/26-31/2025
Alembic Pharmaceuticals Limited Units I & II – 05/26-31/2025. Country: India. Record Type: 483Novel Drug Approvals for 2022
Innovative drugs often mean new treatment options for patients and advances in health care for the American public.FDA Grand Rounds – Anti-biofilm Technologies for Enhancing the Safety of Medical Device Surfaces – 05/29/2025
Anti-biofilm Technologies for Enhancing the Safety of Medical Device Surfaces, May 29, 2025.Meta Forte contains hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Meta Forte, a product promoted and sold for sexual enhancement on various websites, and possibly in some retail stores.Office of Prescription Drug Promotion (OPDP) News
Review the latest news from the Office of Prescription Drug Promotion.Innovative Science and Technology Approaches for New Drugs (ISTAND) Program
The Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program is designed to expand DDT types by encouraging development of DDTs that are out of scope for existing DDT qualification programs but may still be beneficial for drug development.